Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback